|
Chỉ định và Liều dùng
Oral
Hyperphosphataemia in patients with chronic renal failure Adult: As chewable tab/oral powd: Initially, 0.75-2.25 g daily in 3 divided doses. Maintenance dose: 1.5-3 g daily in divided doses. Max: 3.75 g daily. Dose is adjusted every 2-3 wk according to serum phosphate level.
|
|
Cách dùng
Should be taken with food. Take w/ or immediately after meals. Chew thoroughly before swallowing. Do not swallow whole.
|
|
Chống chỉ định
Bowel obstruction, ileus, faecal impaction, hyperphosphataemia.
|
|
Thận trọng
Patient w/ altered GI anatomy (e.g. diverticular disease, peritonitis, history of GI surgery, GI cancer, GI ulceration), hypomotility disorders (e.g. constipation, diabetic gastroparesis), active peptic ulcer, Crohn's disease, ulcerative colitis. Hepatic impairment. Pregnancy and lactation.
|
|
Tác dụng không mong muốn
Significant: GI obstruction, ileus, subileus, GI perforation, faecal impaction.
Nervous: Headache, dizziness, vertigo, asthenia, fatigue, malaise. GI: Nausea, vomiting, diarrhoea, abdominal pain, taste alteration, gastroenteritis, constipation, dyspepsia, flatulence, dry mouth, eructation, IBS, anorexia. Endocrine: Hyperglycaemia, hyperparathyroidism. Haematologic: Eosinophilia. Musculoskeletal: Bone deposition, arthralgia, myalgia, osteoporosis. Dermatologic: Alopecia, sweating. Others: Hypocalcaemia, hyperphosphataemia, hypophosphataemia, hypercalcaemia. |
|
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and vertigo, if affected, do not drive or operate machinery.
|
|
Chỉ số theo dõi
Monitor serum Ca, phosphorus levels.
|
|
Quá liều
Symptoms: Headache, nausea and vomiting. Management: Supportive treatment.
|
|
Tương tác
May reduce bioavailability of quinolones, tetracycline and levothyroxine chloroquine, ketoconazole. May decrease serum concentration of ACE inhibitor, ampicillin, halofantrine.
|
|
Ảnh hưởng đến kết quả xét nghiệm
May produce a radio-opaque appearance on abdominal radiography.
|
|
Tác dụng
Description:
Mechanism of Action: Lanthanum carbonate is a phosphate binder which inhibits the absorption of dietary phosphate from the intestines. It disintegrates in the GI tract to lanthanum ions (La3+) that binds phosphate to make insoluble and unabsorbable lanthanum phosphate complexes, causing a decrease in serum phosphate and Ca levels. Pharmacokinetics: Absorption: Poorly absorbed from the GI tract. Distribution: Plasma protein binding: >99%. Excretion: Mainly via faeces (74%) and urine (<2%). Elimination half-life: 53 hr (plasma); 2-3.6 yr (bone). |
|
Đặc tính
 Source: National Center for Biotechnology Information. PubChem Database. Lanthanum Carbonate, CID=168924, https://pubchem.ncbi.nlm.nih.gov/compound/Lanthanum-Carbonate (accessed on Jan. 22, 2020) |
|
Bảo quản
Store at 25°C. Protect from moisture.
|
|
Phân loại MIMS
|
|
Phân loại ATC
V03AE03 - lanthanum carbonate ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
|
|
Tài liệu tham khảo
Anon. Lanthanum. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 20/07/2017. Buckingham R (ed). Lanthanum Carbonate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/07/2017. Fosrenol Tab Chewable/Powder (Shire US Manufacturing Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 20/07/2017. Joint Formulary Committee. Lanthanum. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/07/2017. McEvoy GK, Snow EK, Miller J et al (eds). Lanthanum Carbonate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 20/07/2017.
|
Đăng xuất
